Apismart 5 mg

Apismart 5 mg Tablets contain apixaban, a direct Factor Xa inhibitor that works by blocking the activity of Factor Xa, an essential enzyme in the coagulation cascade. By inhibiting this factor, apixaban prevents the conversion of prothrombin to thrombin, thereby reducing the formation of fibrin and ultimately decreasing the development of blood clots.

This mechanism of action allows Apismart to effectively reduce the risk of thromboembolic events, such as stroke and deep vein thrombosis (DVT), in patients with conditions like atrial fibrillation or those undergoing certain surgical procedures. Unlike traditional anticoagulants, apixaban does not require routine monitoring, making it a convenient option for long-term anticoagulation therapy.

Side Effects of Apismart 5 mg

Common Side Effects

• Bleeding
• Nausea
• Anemia
• Rash or Allergic Reactions
• Liver Function Changes

Serious Side Effects

• Severe Bleeding
• Allergic Reactions
• Hepatotoxicity
• Thrombocytopenia
• Spinal/Epidural Hematoma

Strengths and Substitutes

• Apismart 2.5 mg

Warnings & Precautions

When using Apismart 5 mg Tablets (apixaban), it’s essential to be aware of the following warnings and precautions:

1. Bleeding Risk:

• Apixaban increases the risk of bleeding, which can be severe and life-threatening. Patients should be monitored for signs of unusual bleeding, such as prolonged bleeding from cuts, unusual bruising, or blood in urine or stools. Patients should inform their healthcare provider immediately if they experience any signs of bleeding.

2. Liver Function:

• Apixaban may affect liver function. Patients with liver disease or those with elevated liver enzymes should be monitored closely, as impaired liver function can increase the risk of bleeding. It may not be appropriate for patients with severe liver impairment.

3. Renal Function:

• Patients with impaired kidney function may require dose adjustments, as reduced renal clearance can lead to increased drug exposure and a higher risk of bleeding. Regular monitoring of kidney function is important.

4. Drug Interactions:

• Apixaban can interact with other medications, including certain anticoagulants, antiplatelet agents, and drugs that affect liver enzymes. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are taking to avoid potential interactions.

5. Surgery and Invasive Procedures:

• Patients may need to discontinue apixaban prior to any surgical or invasive procedures to reduce the risk of bleeding. The timing for discontinuation and resumption of therapy should be discussed with the healthcare provider.

6. Spinal/Epidural Anesthesia:

• Patients receiving spinal anesthesia or undergoing lumbar puncture while on apixaban are at risk for developing spinal or epidural hematomas, which can lead to paralysis. Precautions should be taken to minimize this risk.

7. Pregnancy and Nursing:

• The safety of apixaban during pregnancy and breastfeeding has not been fully established. Patients should discuss potential risks with their healthcare provider if they are pregnant, planning to become pregnant, or are nursing.

Safety Advice

• Regular Monitoring
• Be Alert to Bleeding Signs
• Medication Interactions
• Avoid Certain Activities
• Follow Dosage Instructions
• Pre-Surgery Consultation
• Alcohol Consumption
• Pregnancy and Nursing
• Emergency Information
• Stay Hydrated